DUBLIN–(BUSINESS WIRE)–The “Pain:
GPCR and Nerve Growth Factor-Based Therapies Offer Strong Potential in
Difficult-to-Treat Subtypes” report has been added to ResearchAndMarkets.com’s
offering.
The pain therapeutics market has been largely characterized by only
incremental product innovation over the last decade, as most market
segments continue to be dominated by long-established active
pharmaceutical ingredients and mechanisms of action.
The moderate-to-severe pain space continues to be dominated by opioids,
which are increasingly being reformulated to offer abuse resistance,
whereas mild pain is effectively treated with non-steroidal
anti-inflammatory drugs (NSAIDs). However, significant unmet needs
remain, as chronic pain subtypes-particularly neuropathic pain-do not
respond well to existing therapies.
This report assesses first-in-class innovation across the pain pipeline.
Scope
-
There are 909 pipeline programs in active development for pain. What
proportion of these products are first-in-class? How does
first-in-class innovation vary by development stage and molecular
target class? -
The market for pain treatment is heavily saturated. Which drug classes
are used to treat pain? How do the drug classes in the market compare
with those in the pipelines? -
Which molecular target classes are prominently represented in the
first-in-class pain pipelines? Which first-in-class targets have been
identified as most promising for the treatment of pain? Which
first-in-class products have prior deal involvement?
Reasons to Buy
-
Understand the current disease landscape with an overview of etiology,
pathophysiology, disease classification and staging systems and
epidemiology for major pain subtypes. -
Visualize the composition of the pain market in terms of dominant
molecule types and molecular targets. This knowledge allows a
competitive understanding of gaps in the current market. -
Analyze and compare the pain pipeline and stratify by stage of
development, molecule type, and molecular target. -
Assess the therapeutic potential of first-in-class targets. Using a
proprietary matrix, first-in-class products have been assessed and
ranked according to clinical potential. Promising first-in-class
targets have been reviewed in greater detail. -
Recognize commercial opportunities by identifying first-in-class
pipeline products for pain that have not yet been involved in
licensing or co-development deals, and by analyzing company strategies
in prior deals through case studies of key deals for first-in-class
pain products.
Topics Covered
1 List of Tables & Figures
2 Pain: Executive Summary
2.1 Substantial Unmet Needs Remain in Core Therapy Types
2.2 Highly Diversified Range of Innovative Programs in the Early Pipeline
3 Introduction
3.1 Catalyst
4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Classification
4.3 Sustained Innovation in Pain
4.4 Epidemiology for Pain
4.5 Overview for Marketed Products
5 Assessment of Pipeline Product Innovation
5.1 Overview
5.2 Pipeline by Stage of Development and Molecule Type
5.3 Pipeline by Molecular Target
5.4 Comparative Distribution of Programs Between Pain Market and
Pipeline by Therapeutic Target Family
5.5 Comparative Distribution of First-in-Class and Non-First-in-Class
Pipeline Programs by Molecular Target Class
5.6 Ratio of First-in-Class Programs to First-in-Class Molecular Target
Within the Pipeline
6 First-in-Class Molecular Target Evaluation
6.1 Overview
6.2 Pipeline Programs Targeting Neurotensin Receptor 1
6.3 Pipeline Programs Targeting Matrix Metalloproteinase-9/2
6.4 Pipeline Programs Targeting Beta Nerve Growth Factor
6.5 Pipeline Programs Targeting Pituitary Adenylate Cyclase-Activating
Polypeptide Type I Receptor
6.6 Pipeline Programs Targeting Interleukin-1 Receptor Type 2
6.7 Pipeline Programs Targeting Metabotropic Glutamate Receptor 7
6.8 Pipeline Programs Targeting Transient Receptor Potential Vanilloid
Type 4
6.9 Pipeline Programs Targeting P2X Purinoceptor 7
6.10 Pipeline Programs Targeting Potassium Channel Subfamily K Member 2
7 Key Players and Deals
7.1 Overview
8 Appendix
8.1 Bibliography
8.2 Abbreviations
8.3 Methodology
List of Tables
Table 1: Etiology of Chronic Pain
Table 2: Classification of Pain
Table 3: Fibromyalgia, Total Prevalent Cases, millions (N), 2013-2023
Table 4: Migraine, Total Prevalent Cases, millions (N), 2016-2026
Table 5: Painful Diabetic Neuropathy, Total Prevalent Cases, millions
(N), 2016-2026
Table 6: Trigeminal Neuralgia, Total Prevalent Cases, millions (N),
2012-2022
List of Figures
Figure 1: Pain, Global Market by Molecular Target and Molecule Type, 2019
Figure 2: Pain, Global, Pipeline by Stage of Development and Molecule
Type, 2019
Figure 3: Pain, Global, Pipeline by Molecular Target and Stage of
Development, 2019
Figure 4: Pain, Global, Distribution of Pipeline and Marketed Products
by Molecular Target Class, 2019
Figure 5: Pain, Global, Distribution of Pipeline Products by
First-in-Class Status and Molecular Target Class, 2019
Figure 6: Pain, Global, Percentage Distribution of First-in-Class and
Non-First-in-Class Products by Stage of Development and Molecular Target
Class, 2019
Figure 7: Pain, Global, Ratio of First-in-Class and Non-First-in-Class
Products to First-in-Class Targets by Stage of Development and Molecular
Target Class, 2019
For more information about this report visit https://www.researchandmarkets.com/r/v6qcs
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900